Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing a biotech 10-K stuffed with immunology diagrams is challenging enough; doing it for Q32 Bio Inc. (QTTB), with its dual adaptive- and innate-immunity programs, can feel overwhelming. Trial data for bempikibart and ADX-097, cash-runway math, and dilution clauses are buried across multiple SEC documents.
Our platform turns that complexity into clarity. Stock Titan’s AI delivers line-by-line explanations, transforming Q32 Bio annual report 10-K simplified summaries, pinpointing R&D spend, and flagging risk-factor changes. Need the latest Q32 Bio quarterly earnings report 10-Q filing or want Q32 Bio 8-K material events explained? They appear here moments after hitting EDGAR—complete with section-level highlights you can skim in minutes.
Stay ahead of management moves with Q32 Bio insider trading Form 4 transactions. Our feed shows Q32 Bio Form 4 insider transactions real-time, alerting you to option exercises or sales that may precede clinical milestones. You’ll also find:
- Q32 Bio proxy statement executive compensation parsed into easy tables
- Cash-burn trends and share-issuance details inside every 10-Q
- Quick-read notes that make understanding Q32 Bio SEC documents with AI effortless
Whether you’re dissecting a financing 8-K or searching for Q32 Bio executive stock transactions Form 4, our AI-driven dashboard surfaces the facts that matter. Use the built-in comparison tool for Q32 Bio earnings report filing analysis across quarters, monitor trial updates without wading through pages of technical jargon, and make informed decisions faster.
Q32 Bio Inc. (QTTB) announced it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart for alopecia areata. The company disclosed the update via a press release titled “Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata,” furnished as Exhibit 99.1.
Jodie Pope Morrison, who serves as CEO and Director of Q32 Bio Inc. (QTTB), reported the automatic sale of 10,494 shares of common stock to satisfy tax withholding obligations from vested restricted stock units. The sales occurred on 08/26/2025 (deemed execution 08/27/2025) at a weighted average price reported as $1.801, with per-share prices ranging across two trading days from $1.73 to $1.96. Following the transactions, the reporting person beneficially owns 121,506 shares directly. The filing was signed by an attorney-in-fact on 08/28/2025.
Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette reported the sale of 2,990 shares of common stock on 08/26/2025 with a weighted average price of $1.801 per share. The filing states the sales were automatic to satisfy tax withholding obligations related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the transaction, Ms. Violette directly beneficially owns 58,384 shares and indirectly holds 36,277 shares through Violette Holdings LLC, of which she is a manager and disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. (QTTB) insider sale by CFO/President Lee Kalowski: The filing shows an automatic sale on 08/26/2025 of 4,240 shares of common stock to cover tax withholding from vested restricted stock units, reported at a weighted-average price of $1.801 per share. After the sale the reporting person beneficially owned 49,010 shares, held directly. The filing notes the shares were sold in multiple transactions over two consecutive trading days at per-share prices ranging $1.81–$1.96 and $1.73–$1.83. The form is signed by an attorney-in-fact on 08/28/2025.
Q32 Bio (NASDAQ:QTTB) announced the resignation of Chief Medical Officer Jason Campagna, M.D., Ph.D., effective July 9, 2025. The company has appointed Adrien Sipos, M.D., Ph.D. as Interim Chief Medical Officer, effective the same date. This Form 8-K filing discloses the leadership transition in the company's medical division.
FAQ
What is the current stock price of Q32 BIO (QTTB)?
What is the market cap of Q32 BIO (QTTB)?
